Angiodynamics

Eximo Medical Ltd. develops hybrid catheter technology for tissue resection invascular and gastrointestinal endoluminal applications. The company’s technology includes CatHI, a single-use hybrid catheter that provides optical fibers that deliver short laser pulse, and a blunt mechanical knife. Its clinical applications also comprise lead extraction and peripheral artery disease. The company was founded in 2012 and is based in Modi'in-Maccabim-Re'ut, Israel. As of October 2, 2019, Eximo Medical Ltd. operates as a subsidiary of AngioDynamics, Inc.

RadiaDyne, L.L.C., based in Houston, Texas, is a medical diagnostic and device company that specializes in patient dose monitoring technology for cancer patients undergoing radiation treatments. Founded in 2007, the company offers a radiation dose monitoring platform that provides high-accuracy dose readings without the need for correction factors. Its technology enables real-time, precise measurement and includes proprietary intracavitary delivery devices. By focusing on enhancing the safety and effectiveness of radiation therapy, RadiaDyne aims to reduce side effects and improve patient outcomes in cancer treatment. The company operates as a subsidiary of AngioDynamics, Inc.

Navilyst Medical Inc., headquartered in Marlborough, MA, was formed in February 2008 from Boston Scientific’s Fluid Management and Vascular Access business units. Its breakthrough devices, including the PASV:registered: Valve Technology, expanded line of Xcela:registered: Power Injectable PICCs and world-leading NAMIC:registered: Fluid Management products, help hospitals to achieve safe, favorable outcomes for patients. The Company distributes its products worldwide and has its lead U.S. manufacturing facility in Glens Falls, NY. The name Navilyst combines the navi– of navigation and the –lyst of catalyst, encompassing how a leading medical technology enterprise drives industry-changing innovation.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

RITA Medical Systems develops, manufactures and markets innovative products for patients with solid cancerous or benign tumors. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. While the Company's current focus is on liver cancer and metastatic bone cancer, the Company believes that its minimally invasive technology may in the future be applied to other types of tumors, including tumors of the lung, breast, uterus, prostate and kidney. The Company has received regulatory clearance in major markets worldwide, including the United States. In March 2000, RITA became the first radiofrequency ablation company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone. The Company has sold over 40,000 of its disposable devices throughout the world.